RE: Price isn't rite12 Sep 2025 08:21
Every single share I ever invested in never made the timescale originally laid out.
Virtually all shares as the crunch day approaches and over the original timescale falls in value, with many incredibly low, so that aspect is nothing new.
The government was always going to get a share, so the increase in the amount they can take in the 2023 code is marginal.
I think AISC costings are a complete disaster without a complete webpage dedicated to this. One factor alone without going into more boring detail is we don't even know the parameter of the average Spodumene price used in the calculation. It could be 1,600 dollars to 2,500, 680 dollars to 3,400 dollars, anything, without that and other detail the technical amongst us can't make any estimates. For less technical there is no simple explanation or parallel cost simplified. So not good for prospecting investors.
The path forward beyond revenue is equally important. If Nielle is extremely close to a maiden value that would influence investors, if it is March next year not so much.
Fatou is a little further away but we have no timescale.
Bernard often talks about purchasing something else. But we don't know if this will be very early stage and cheap or later stage and a bit more money.
So I don't see why anyone expects a large share price now, those people baffle me completely.
All looking good, get the product exported and all of those millions in stock into our KMUK bank account and hear Bernard lay out the future in detail. The market will take a view.
Sign In
Follow the stocks
